TrialBMC infectious diseases2024

Real-world evidence of a novel tetravalent immunoglobulin Y effectiveness and safety in patients with the refractory Helicobacter pylori infection.

Nan Hao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.